PPA
BPMC

Parametric Portfolio Associates’s Blueprint Medicines BPMC Stock Holding History

Parametric Portfolio Associates’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$3.24M Sell
50,770
-19,459
-28% -$1.4M ﹤0.01% 2134
2021
Q4 		$7.52M Buy
70,229
+8,720
+14% +$912K ﹤0.01% 1581
2021
Q3 		$6.32M Buy
61,509
+3,025
+5% +$282K ﹤0.01% 1669
2021
Q2 		$5.14M Sell
58,484
-6,491
-10% -$595K ﹤0.01% 1836
2021
Q1 		$6.32M Sell
64,975
-15,130
-19% -$1.51M ﹤0.01% 2013
2020
Q4 		$8.98M Buy
80,105
+22,689
+40% +$2.39M 0.01% 1652
2020
Q3 		$5.32M Buy
57,416
+1,464
+3% +$113K ﹤0.01% 1848
2020
Q2 		$4.36M Buy
55,952
+2,404
+4% +$163K ﹤0.01% 1967
2020
Q1 		$3.13M Buy
53,548
+4,433
+9% +$285K ﹤0.01% 2083
2019
Q4 		$3.94M Buy
49,115
+2,313
+5% +$173K ﹤0.01% 2229
2019
Q3 		$3.44M Buy
46,802
+20,949
+81% +$1.81M ﹤0.01% 2296
2019
Q2 		$2.44M Buy
25,853
+8,799
+52% +$726K ﹤0.01% 2530
2019
Q1 		$1.36M Sell
17,054
-2,509
-13% -$185K ﹤0.01% 2867
2018
Q4 		$1.05M Sell
19,563
-16,243
-45% -$987K ﹤0.01% 2949
2018
Q3 		$2.79M Buy
35,806
+10,570
+42% +$735K ﹤0.01% 2472
2018
Q2 		$1.6M Buy
25,236
+18
+0.1% +$1.43K ﹤0.01% 2814
2018
Q1 		$2.31M Buy
25,218
+3,237
+15% +$279K ﹤0.01% 2516
2017
Q4 		$1.66M Buy
21,981
+7,844
+55% +$552K ﹤0.01% 2729
2017
Q3 		$985K Buy
14,137
+1,299
+10% +$69.4K ﹤0.01% 3054
2017
Q2 		$651K Buy
12,838
+3,454
+37% +$147K ﹤0.01% 3213
2017
Q1 		$375K Buy
+9,384
New +$336K ﹤0.01% 3340

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCM
Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Parametric Portfolio Associates's BPMC Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Blueprint Medicines (BPMC) stake by 28% in Q1 2022, selling an estimated $1.4M and leaving 50,770 shares worth $3.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2134.

Parametric Portfolio Associates first reported a position in BPMC in Q1 2017 and has held it in 21 quarters since. The position peaked at $8.98M in Q4 2020. 249 funds tracked by Wall St. Rank hold BPMC as of Q1 2022.

  • Parametric Portfolio Associates held 50,770 shares of Blueprint Medicines worth $3.24M as of Q1 2022.
  • Parametric Portfolio Associates sold 19,459 Blueprint Medicines shares in Q1 2022, an estimated $1.4M.
  • Blueprint Medicines made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #2134 holding.
  • Parametric Portfolio Associates first reported a position in Blueprint Medicines in Q1 2017 and has held it in 21 quarters since.
  • Parametric Portfolio Associates's Blueprint Medicines position peaked at $8.98M in Q4 2020.
  • 249 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.